Asivatrep, a selective antagonist of TRPV1, improved the clinical signs and symptoms of AD and was well tolerated in a phase 3 randomized, vehicle-controlled study with patients aged above 12 years with mild to moderate AD [107]. The gene discussed is TRPV1; the disease is Alzheimer disease.